These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29468947)

  • 1. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Cree BA
    Mult Scler; 2018 Aug; 24(9):1161-1162. PubMed ID: 29468947
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Wallin MT
    Mult Scler; 2018 Aug; 24(9):1159-1161. PubMed ID: 29468931
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Piehl F; Hillert J
    Mult Scler; 2018 Aug; 24(9):1157-1159. PubMed ID: 29468952
    [No Abstract]   [Full Text] [Related]  

  • 4. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.
    AbdelRazek MA; Casasola M; Mollashahi R; Brodski A; Morin S; Augustynowicz A; Jassim S; Matiello M; Sloane J
    Mult Scler Relat Disord; 2022 Mar; 59():103505. PubMed ID: 35121247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
    Chin P; Chan AC
    Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    Alcalá C; Quintanilla-Bordás C; Gascón F; Sempere ÁP; Navarro L; Carcelén-Gadea M; Landete L; Mallada J; Cañizares E; Belenguer A; Carratalá S; Domínguez JA; Pérez-Miralles FC; Gil-Perotín S; Gasqué R; Cubas L; Castillo J; Casanova B
    J Neurol; 2022 Jul; 269(7):3676-3681. PubMed ID: 35107597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
    Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
    Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocrelizumab, edaravone, and valbenazine.
    Hussar DA; Hussar TL
    J Am Pharm Assoc (2003); 2017; 57(4):551-554. PubMed ID: 28712464
    [No Abstract]   [Full Text] [Related]  

  • 12. Ocrelizumab: A Review in Multiple Sclerosis.
    Syed YY
    CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective].
    Lalive PH
    Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606
    [No Abstract]   [Full Text] [Related]  

  • 14. New biological agents in the treatment of multiple sclerosis.
    Buc M
    Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
    Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
    Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.
    Marrodan M; Laviano J; Oneto S; Reino FM; Delorme R; Fornillo F; Férnandez J; Correale J
    Neurol Sci; 2021 Sep; 42(9):3893-3895. PubMed ID: 34075515
    [No Abstract]   [Full Text] [Related]  

  • 17. New Inroads Against Multiple Sclerosis.
    Lyon J
    JAMA; 2018 Jan; 319(1):9-11. PubMed ID: 29238808
    [No Abstract]   [Full Text] [Related]  

  • 18. Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.
    Sormani MP; De Stefano N
    Neurology; 2014 Apr; 82(17):1484-5. PubMed ID: 24682968
    [No Abstract]   [Full Text] [Related]  

  • 19. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
    Capasso N; Nozzolillo A; Scalia G; Lanzillo R; Carotenuto A; De Angelis M; Petruzzo M; Saccà F; Russo CV; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2021 Apr; 49():102802. PubMed ID: 33556652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    Baber U; Bouley A; Egnor E; Sloane JA
    J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.